Telavancin (TLV) is Active Against Experimental Aortic Valve Endocarditis Caused by Daptomycin-Resistant (DAP-R) Methicillin-Resistant Staphylococcus aureus (MRSA) Strains.

Related Articles

Telavancin (TLV) is Active Against Experimental Aortic Valve Endocarditis Caused by Daptomycin-Resistant (DAP-R) Methicillin-Resistant Staphylococcus aureus (MRSA) Strains.

Antimicrob Agents Chemother. 2016 Nov 21;:

Authors: Abdelhady W, Bayer AS, Gonzales R, Li L, Xiong YQ

Abstract
We compared the efficacy of TLV and DAP in an experimental rabbit endocarditis model caused by two clinically-derived DAP-R MRSA strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture-negative as compared to untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAP-R MRSA isolates in this invasive endovascular infection model.

PMID: 27872064 [PubMed - as supplied by publisher]